The Valens Company Enters into Extraction and Custom Manufacturing Agreement with Rubicon Organics
The Valens Company (OTCQX: VLNCF) has announced a strategic alliance with Rubicon Organics, a leading organic cannabis producer in Canada. This custom manufacturing agreement allows Valens to utilize its extraction technologies to create innovative cannabis products. The partnership aims to enhance Rubicon's portfolio with certified organic products and to accelerate the launch of its 2.0 product line, catering to the premium cannabis market. Valens CEO Tyler Robson expressed confidence in Rubicon's capabilities to thrive across various product categories.
- Collaboration with Rubicon Organics enhances product portfolio and market reach.
- Utilization of advanced extraction technologies potentially increases product quality.
- Accelerated development of organic certified 2.0 cannabis products may boost sales.
- None.
Two of the largest certified organic producers in Canada come together to bring innovative and
high-quality products to market
KELOWNA, BC, March 3, 2021 /PRNewswire/ - The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF) (the "Company," "The Valens Company" or "Valens"), a leading manufacturer of cannabis products, today announced that it has entered into an extraction and custom manufacturing agreement with Rubicon Organics, a Canadian licensed producer of high-quality, organic certified, sustainably grown cannabis. Rubicon Organics boasts a robust portfolio of recreational brands that meet the diversified needs of consumers, including super-premium Simply Bare Organic, flower-based 1964 Supply Co., in addition to concentrate-focused Lab Theory.
Under the terms of the agreement, Valens will have the opportunity to leverage its full complement of proprietary extraction capabilities, including organic certified CO2, ethanol, and other extraction technologies, to deliver customized consumer experiences in a variety of 2.0 products under the Rubicon Organics portfolio. Additionally, the custom manufacturing agreement provides a platform for collaboration, new product development and innovation to bring next generation formats to the market, allowing Valens to further expand its industry-leading portfolio of product manufacturing capabilities.
"The Rubicon Organics team has a strong and proven track record of success with their flower business and we are confident they will enjoy the same success in other product categories," said Tyler Robson, Chief Executive Officer, Co-Founder and Chair of The Valens Company. "At the heart of this agreement is a true partnership and both parties are eager to get down to work on innovation to bolster Rubicon Organics' product portfolio and bring certified organic, high-quality 2.0 products to the Canadian market. We are especially pleased to be working with a supply partner that can meet our strict requirements for laboratory controls, quality and reliability."
"This agreement will enable Rubicon Organics to accelerate the launch of our organic certified 2.0 innovation pipeline, providing our consumers with the best cannabis products in Canada, and growing our share of the premium and super premium cannabis category," said Jesse McConnell, Chief Executive Officer of Rubicon Organics.
At Valens, it's Personal.
About The Valens Company
The Valens Company is a leading manufacturer of cannabis products with a mission to bring the benefits of cannabis to the world. The Company provides proprietary cannabis processing services across five core technologies, in addition to best-in-class product development, formulation and manufacturing of cannabis consumer packaged goods. The Valens Company's high-quality products are exclusively formulated for the medical, therapeutic, health and wellness, and recreational consumer segments, and are offered across numerous product formats, including oils, vapes, concentrates, edibles and topicals, as well as pre-rolls, with a focus on next-generation product development and innovation. Its breakthrough patented emulsification technology, SōRSE™ by Valens, converts cannabis oil into water-soluble emulsions for seamless integration into a variety of product formats, allowing for near-perfect dosing, stability, and taste. In partnership with brand houses, consumer packaged goods companies and licensed cannabis producers around the globe, the Company continues to grow its diverse product portfolio in alignment with evolving cannabis consumer preferences in key markets. Through its wholly owned subsidiary Valens Labs Ltd., the Company is setting the standard in cannabis testing and research and development with Canada's only ISO17025 accredited analytical services lab, named The Centre of Excellence in Plant-Based Science by partner and scientific world leader Thermo Fisher Scientific. Discover more on The Valens Company and its subsidiaries at http://www.thevalenscompany.com.
Notice regarding Forward Looking Statements
All information included in this news release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management's expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management's current expectations and plans relating to the future. Wherever possible, words such as "plans", "expects", "scheduled", "trends", "indications", "potential", "estimates", "predicts", "anticipate", "to establish", "believe", "intend", "ability to", or statements that certain actions, events or results "may", "could", "would", "might", "will", or are "likely" to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, all disclosure regarding future results of operations, economic conditions and anticipated courses of action. Investors and other parties are advised that there is not necessarily any correlation between the number of SKUs manufactured and shipped and revenue and profit, and undue reliance should not be placed on such information.
The risks and uncertainties that may affect forward-looking statements include, among others, that the LYF Acquisition does not close, the Milestones are not met, the increase to the Company's EBITDA and diluted EPS is not achieved, regulatory risk, United States border crossing and travel bans, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, reliance on a single facility, limited operating history, vulnerability to rising energy costs, unfavourable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company's latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company's website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management's current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.
Jeff Fallows, The Valens Company, Investor Relations, ir@thevalenscompany.com, 1 647.956.8254; KCSA Strategic Communications, Phil Carlson / Elizabeth Barker, VLNS@kcsa.com, 1 212.896.1233 / 1 212.896.1203; Media: KCSA Strategic Communications, Anne Donohoe, adonohoe@kcsa.com, 1 212.896.1265
View original content to download multimedia:http://www.prnewswire.com/news-releases/the-valens-company-enters-into-extraction-and-custom-manufacturing-agreement-with-rubicon-organics-301239176.html
SOURCE The Valens Company Inc.
FAQ
What is the recent partnership announced by Valens Company (VLNCF)?
How will the agreement with Rubicon Organics benefit Valens Company (VLNCF)?
What are the expected outcomes of the Valens and Rubicon Organics agreement?
When was the partnership between Valens Company and Rubicon Organics announced?
